BRITONS receive a dose of the AstraZeneca vaccine at Lichfield cathedral, which has been converted into a temporary vaccination centre.—AFP
BRITONS receive a dose of the AstraZeneca vaccine at Lichfield cathedral, which has been converted into a temporary vaccination centre.—AFP

AMSTERDAM: The EU’s drug watchdog said on Thursday it is still convinced the benefits of AstraZeneca’s Covid-19 vaccine outweigh the risks following an investigation into reports of blood disorders that prompted more than a dozen nations to suspend its use.

The news came as the European Medicines Agency (EMA) director Emer Cooke said the watchdog could not definitively rule out a link between blood clot incidents and the vaccine in its investigation into 30 cases of a rare blood clotting condition.

But she said in a briefing the “clear” conclusion of the review was that the vaccine “benefits in protecting people from Covid-19 with the associated risk of death or hospitalisation outweighs the possible risks.”

The agency will however update its guidance to include an explanation about the potential risks on both the patient leaflet and in the information for healthcare professionals, she said. “This is a safe and effective vaccine,” said Cooke.

The agency has been under growing pressure to clear up safety concerns after a small number of reports in recent weeks of bleeding, blood clots and low platelet counts in people who have received the shot.

The agency’s review covering 5 million people, included 30 cases of unusual blood disorders in people in the European Economic Area (EEA), which links 30 European countries.

The EMA’s focus and primary concern has been on cases of blood clots in the head, a rare condition that’s difficult to treat called cerebral venous thrombosis (CVT) or a subform known as cerebral venous sinus thrombosis (CVST).

More than 45 million of the shots have been administered across the EEA.

At least 13 European countries, including France, Germany and Italy, have stopped administering the shot pending the review.

Britain’s medicines regulator said on Thursday it was investigating five cases of CVST among people given AstraZeneca’s vaccine but it reaffirmed that the benefits of the shot far outweighed any possible risks.

The World Health Organisation also this week reaffirmed its support for the shot.

AstraZeneca has said a review covering more than 17 million people who had received its shots in the EU and Britain had found no evidence of an increased risk of blood clots.

Many governments have said the decision to pause inoculations was out of an abundance of caution.

But experts have warned the political interference could undermine public confidence and hobble the bloc’s slow vaccination campaign as governments struggle to tame more infectious variants.

The bloc’s vaccine roll-out has lagged the United States and former EU member Britain.

Published in Dawn, March 19th, 2021

Opinion

Editorial

Ultimate price
Updated 02 Nov, 2024

Ultimate price

To dismantle culture of impunity for crimes against journalists, state must ensure that perpetrators do not go unpunished.
Mastung bombing
02 Nov, 2024

Mastung bombing

INSTABILITY continues to haunt Balochistan, as Friday morning’s bombing in Mastung has shown. At least nine...
Plane speak
02 Nov, 2024

Plane speak

DESPITE all its efforts to facilitate PIA’s privatisation, it seems the government only ended up being taken for a...
Seeking investment
Updated 01 Nov, 2024

Seeking investment

Foreign visits will be fruitless unless crucial structural, policy reforms directly affecting investors are focused.
State-backed terror
01 Nov, 2024

State-backed terror

OVER the past year or so, India’s reportedly malign activities in foreign countries have increasingly come under the radar, with
Shared crisis
01 Nov, 2024

Shared crisis

WITH Lahore experiencing unprecedented levels of smog, the Punjab government has announced a series of “green...